Towards the development of an epitope-focused vaccine for SARS-CoV-2
Por:
Cervantes-Torres, Jacquelynne, Rosales-Mendoza, Sergio, Cabello, Carlos, Montero, Laura, Hernandez-Aceves, Juan, Granados, Guillermo, Calderon-Gallegos, Arturo, Zúñiga-Flores F., Ruiz-Rivera, Mirna, Abarca-Magaña J.C., Ortega-Francisco, Sandra, Olguin-Alor, Roxana, Diaz, Georgina, Paczka-Garcia, Filipo, Zavala-Gaytan, Rubi, Vazquez-Ramirez, Ricardo, Ayón-Nuñez D.A., Carrero J.C., Rios, Diana, Jasso-Ramirez, Mariana, Vazquez-Hernandez, Rebeca, Venegas, David, Garzon, Daniel, Cobos, Laura, Segura-Velazquez, Rene, Villalobos, Nelly, Meneses, Gabriela, Zúñiga J., Gamba, Gerardo, Cardenas, Graciela, Hernandez, Marisela, Parkhouse, Michael E., Romano, Marta C., Alonso Herrera L., Bobes, Raul J., Perez-Tapia, Mayra, Huerta, Leonor, Fierro, Nora, Gracia, Isabel, Soldevilla, Gloria, Fragoso, Gladis, Suarez-Guemes, Francisco, Laclette, Juan P., Sciutto, Edda
Publicada:
1 ene 2022
Resumen:
The rapid spread of COVID-19 on all continents and the mortality induced by SARS-CoV-2 virus, the cause of the pandemic coronavirus disease 2019 (COVID-19) has motivated an unprecedented effort for vaccine development. Inactivated viruses as well as vaccines focused on the partial or total sequence of the Spike protein using different novel platforms such us RNA, DNA, proteins, and non-replicating viral vectors have been developed. The high global need for vaccines, now and in the future, and the emergence of new variants of concern still requires development of accessible vaccines that can be adapted according to the most prevalent variants in the respective regions. Here, we describe the immunogenic properties of a group of theoretically predicted RBD peptides to be used as the first step towards the development of an effective, safe and low-cost epitope-focused vaccine. One of the tested peptides named P5, proved to be safe and immunogenic. Subcutaneous administration of the peptide, formulated with alumina, induced high levels of specific IgG antibodies in mice and hamsters, as well as an increase of IFN-? expression by CD8+ T cells in C57 and BALB/c mice upon in vitro stimulation with P5. Neutralizing titers of anti-P5 antibodies, however, were disappointingly low, a deficiency that we will attempt to resolve by the inclusion of additional immunogenic epitopes to P5. The safety and immunogenicity data reported in this study support the use of this peptide as a starting point for the design of an epitope restricted vaccine. © 2022 Elsevier Ltd
Filiaciones:
Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Ciudad Universitaria s/n, Ciudad de México, Ciudad de México, 04510, Mexico
Laboratorio de Biofarmacéuticos Recombinantes, Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, Av. Dr. Manuel Nava 6, S.L.P, 78210, Mexico
Sección de Biotecnología, Centro de Investigación en Ciencias de la Salud y Biomedicina, Universidad Autónoma de San Luis Potosí, Av. Sierra Leona 550, Lomas 2ª Sección, San Luis Potosí, 78210, Mexico
Instituto Nacional de Enfermedades Respiratorias “Ismael Cosio Villegas”, Calz. de Tlalpan 4502, Belisario Domínguez Secc. 16, Tlalpan, Ciudad de México, 14080, Mexico
Facultad de Medicina Veterinaria y Zootecnia, Universidad Nacional Autónoma de México, Ciudad Universitaria s/n, Ciudad de México, Ciudad de México, 04510, Mexico
Instituto de Diagnóstico y Referencia Epidemiológica “Dr. Manuel Martínez Báez”, Francisco de P. Miranda 177, Lomas de Plateros, Álvaro Obregón, Ciudad de México, 01480, Mexico
Instituto Nacional de Ciencias Médicas y Nutrición “Salvador Zubirán”, Vasco de Quiroga 15, Belisario Domínguez Secc. 16, Tlalpan, Ciudad de México, 14080, Mexico
Instituto Nacional de Neurología y Neurocirugía. Av. Insurgentes Sur 3877, La Fama, Tlalpan, Ciudad de México, 14269, Mexico
Instituto Gulbekian de Ciência, Portugal. R. Q.ta Grande 6, Oeiras, 2780-156, Portugal
Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Av. Instituto Politécnico Nacional 2508, San Pedro Zacatenco, Gustavo A. Madero, Ciudad de México, 07360, Mexico
Instituto Nacional de Medicina Genómica, Periférico Sur 4809, Arenal Tepepan, Ciudad de México, 4610, Mexico
Unidad de Desarrollo e Investigación en Bioprocesos, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Prolongación de Carpio y Plan de Ayala S/N, Col. Casco de Santo Tomas, Del. Miguel Hidalgo, Ciudad de México, C.P 11340, Mexico
Facultad de Química, Universidad Nacional Autónoma de México, Ciudad Universitaria s/n, Ciudad de México, Ciudad de México, 04510, Mexico
Green Published, Bronze, All Open Access, Green
|